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Abstract
Introduction:  Although systemic T-cell responses against tumor antigens and tumor infiltration by T cells have been
investigated in colorectal cancer (CRC), the initiation of spontaneous immune responses in situ is not well understood.
Macrophages and dendritic cells (DC) play an important role as a link between innate and adaptive immune response. The aim
of the present study was to analyze macrophage and DC infiltration in CRC and to investigate whether there is a correlation to
systemic T-cell response, regulatory T cell (Treg) infiltration, and survival.
Methods: Immunohistological staining was performed with nine markers for macrophages and DC (CD68, CD163, S100,
CD11c, CD208, CD209, CD123, CD1a, Langerin) in 40 colorectal cancer samples from patients, in whom the state of systemic
T-cell responses against tumor-associated antigens (TAA) and Treg infiltration had previously been determined.
Results: All specimens contained cells positive for CD68, CD163, S100 and CD1a in epithelial tumor tissue and tumor stroma.
Only a very few (less than median 3/HPF) CD123+, CD1a+, CD11c+, CD 208+, CD209+, or Langerin+ cells were detected in
the specimens. Overall, we found a trend towards increased infiltration by S100-positive DC and a significantly increased number
of stromal S100-positive DC in patients without T-cell response. There was an increase of stromal S100 DC and CD163
macrophages in limited disease (S100: 11.1/HPF vs. 7.3/HPF, p = 0.046; CD163: 11.0/HPF vs. 8.1/HPF, p = 0.06). We found a
significant, positive correlation between S100-positive DC and FOXP3-positive Tregs. Survival in patients with high DC
infiltration was significantly better than that in those with low DC infiltration (p < 0.05). Furthermore, we found a trend towards
better survival for increased infiltration with CD163-positive macrophages (p = 0.07).
Conclusion: The present in situ study adds new data to the discussion on the interaction between the innate and adoptive
immune system. Our data strongly support the hypothesis that tumor-infiltrating DC are a key factor at the interface between
innate and adaptive immune response in malignant disease. Tumor infiltrating S100-positive DC show an inverse relationship
with the systemic antigen-specific T-cell response, a positive correlation with regulatory T cells, and a positive association with
survival in CRC. These data put tumor-infiltrating DC at the center of the relevant immune response in CRC.
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Introduction
Colorectal cancer (CRC) is a common malignant disease,
which has been intensely studied for tumor-immune
interactions to develop successful immunotherapies. In
particular, systemic T-cell responses against tumor anti-
gens and tumor-infiltrating T cells have been analyzed in
detail in CRC. Several investigators have linked a high T
cell infiltration to a better survival in CRC [1-6]. Patients
with CRC – as well as those with other malignant diseases
– are able to mount an antigen-specific T cell response
without prior immunotherapy [7,8]. In a first analysis
with a limited number of colorectal cancer patients, no
survival benefit was found for patients with peripheral
TAA-directed T-cell responses [9]. Various components
including the immune system, tumor stroma and tumor
cells themselves influence the induction and modulation
of tumor-directed immune responses [10]. Limited anti-
tumor activity of spontaneous antigen-specific T cells at a
clinical level in CRC patients may be due to multiple fac-
tors.
Approximately 20 years ago, mononuclear phagocytes
were described for the first time as being increased in CRC
compared to healthy tissue [11]. This observation has
been confirmed several times, for example, just recently
by Sickert and co-workers [12]. Furthermore, it has been
known for about the same amount of time that high num-
bers of tumor-associated macrophages (TAM) and tumor-
associated DC (TADC) are related to a better survival in
CRC [13-15]. This also agrees with data in other malig-
nant diseases [16,17]. For tumor-infiltrating macro-
phages, it is controversially discussed in the literature
whether a trend towards high macrophage infiltration in
CRC is a positive prognostic factor [3,5,18-21].
Dendritic cells, i.e. professional antigen-presenting cells,
play a critical role in innate and adaptive immune
responses [22]. In the development of spontaneous T-cell
responses, the interaction between DC and other com-
partments of the immune system (Tregs, T cells) is of cen-
tral importance. In a previous work, we showed that the
average Treg infiltration rate in the tumor was slightly
higher in patients without systemic TAA-specific T-cell
response and that Treg infiltration in the tumor stroma
was significantly higher in limited disease than in meta-
static CRC [23]. Understanding the role of resident DC in
relation to local Tregs and systemic immune response
might offer great potential in the context of active-specific
vaccination against cancer and the mediation of systemic
immunotherapies at the tumor site [24-26].
The aim of the present study was to analyze colorectal can-
cer infiltration by macrophages and dendritic cells of var-
ious phenotypes in situ and to test whether there is a
correlation to a systemic TAA-specific T-cell response,
local infiltration by regulatory T cells, disease stage and
survival of CRC patients.
Methods
Patient selection, immunohistochemistry and T cell assays
After institutional review board approval and informed
consent, peripheral blood mononuclear cells from CRC
patients were collected and frozen for T cell analysis. All
analyses were performed in compliance with the Helsinki
Declaration. HLA-A2-positive patients were tested for the
presence of T-cell responses against the HLA-A*0201-pre-
sented T cell epitopes Ep-CAM p263-271, her-2/neu p654-
662, and CEA p571-579 by ELISPOT assay. HLA analysis
and ELISPOT were performed as previously described
[7,8]. Positive T-cell responses were also defined as previ-
ously described [7-9]. Immunohistochemistry for FOXP3,
CD3, and CD8 had been performed on the same patient
samples earlier [23]. Sufficient tumor sections for immu-
nohistochemistry and sufficient clinical cancer were
required for inclusion.
Immunohistochemistry and microscopic analysis
For immunostaining, 4 µm thick sections were cut, de-
paraffinized, and subjected to heat-induced epitope
retrieval before incubation with antibodies. For this pur-
pose, sections were immersed in sodium citrate buffer at
pH 6.0 and heated in a high-pressure cooker. After cook-
ing, the slides were rinsed in running water, washed with
Tris-buffered saline, pH 7.4 and incubated with the pri-
mary antibodies. All primary antibodies employed are
listed in Table 1. For double labelling S100/CD163, slides
were incubated with the polyclonal rabbit antibody
against S100 protein, blocked using a commercial peroxi-
dase-blocking reagent and developed using the streptavi-
din peroxidase kit (Dako, Glostrup, Denmark). Sections
were then incubated with the mouse monoclonal anti-
body against CD163, and the streptavidin AP kit (Dako)
was used for detection. Alkaline phosphatase was devel-
oped using Fast Red as the chromogen, while peroxidase
was visualized with diaminobenzidine chromogen as the
substrate. Tonsillar tissue with follicular hyperplasia
served as positive controls, and negative controls were
performed by omitting the primary antibodies. Ten ran-
domly chosen high power fields (1 HPF = 0,237 mm2)
were analyzed for macrophage or dendritic cell infiltra-
tion in the tumor tissue and the tumor stroma and aver-
aged in each case.
Statistical and survival analysis
TAM/TADC infiltration and systemic T-cell response
Patients were sorted according to their positive or negative
peripheral T-cell response. The infiltration with TAM/
TADC in these two groups was compared using the Stu-
dent's t-test, separately for epithelial and stromal infiltra-
tion.Journal of Translational Medicine 2007, 5:62 http://www.translational-medicine.com/content/5/1/62
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TAM/TADC infiltration and survival
All patients were sorted according to their TAM or TADC
infiltration. The median was used to separate patients
with high and low infiltration. A Kaplan-Meier survival
analysis was performed comparing patients with high and
low infiltration. A log-rank test was performed to test sta-
tistical significance.
Stage correction
We then compiled patient groups according to their dis-
ease stage to reduce the influence of external factors. Stage
correction was performed by grouping patients by their
UICC stage. We combined UICC I and II because only one
patient was UICC I. These stage-grouped patients were
sorted by TAM/TADC infiltration. The median was again
used to separate patients with infiltration lower or higher
than the median. All patients with low infiltration in stage
group I+II, III, and IV were combined into a new "stage-
corrected low infiltration group". A "stage-corrected high
infiltration group" was similarly defined. These two
groups were then compared using Kaplan-Meier survival
analysis. A log-rank test was performed to test statistical
significance.
Association of TAM/TADC infiltration and stage, age, and gender
To analyze differences concerning TAM/TADC infiltration
and stage, patients were grouped according to limited
(UICC I and II) and metastatic (UICC III and IV) disease.
These two groups were compared for tumor and stromal
infiltration by TAM and TADC using the Student's t-test.
We also tested the association between TAM/TADC infil-
tration and age (Pearson's correlation) and gender (t-test).
Correlation of TAM/TADC with tumor-infiltrating T cells
Pearson's correlation was calculated for TAM and TADC
infiltration with tumor-infiltrating Tregs, CD3+ T cell, and
CD8+ T cell infiltration and separately for stromal and
epithelial tumor infiltration. Since correlations between
the various tumor-infiltrating immune cells have to be
considered descriptive due to multiple testing, we addi-
tionally performed a Bonferroni correction.
A level of p < 0.05 was considered significant and p < 0.1
a trend. SPSS software was used.
Results
Patient characteristics
Forty CRC patients met all inclusion criteria. These are the
same 40 patients previously published for their Treg infil-
tration [23]. One patient had UICC I, 20 patients UICC II,
six patients UICC III, and 13 patients UICC IV. Eleven
patients tested positively for a systemic TAA-specific T-cell
response to HLA-A2-binding peptides of CEA, Ep-CAM,
and/or her-2/neu. Twenty-one patients were female and
nineteen male. Mean age at first diagnosis was 62.1 years
(patients with T-cell response: 61.7 years, patients without
T-cell response: 62.2 years).
General description of macrophage and DC infiltration
We found an infiltration of tumor stroma and epithelial
tumor tissue by CD68- and CD163-positive macrophages
and S100-expressing dendritic cells in all 40 specimens as
summarized in Table 2. The frequency of CD68-, S100-,
CD163-, and CD209-positive cells was significantly
higher in stromal than in epithelial tumor tissue. Lang-
erin-, CD208-, and CD123-positive cells were very rare.
Examples are given in Figure 1.
Double staining of CD163 and S100
Double staining revealed that approximately 20% of
S100-positive cells were also positive for CD163, indicat-
ing that, with our staining protocol, only a relatively small
percentage of macrophages were also labeled with the
anti-S100 antibody and only S100+/CD163- cells were
regarded as DC.
Macrophage/DC infiltration and systemic T-cell response
There is a trend towards increased infiltration by S100-
positive dendritic cells in patients without systemic T-cell
response compared to those with systemic T-cell response
(12.8/HPF vs. 8.1 HPF, p = 0.07). This trend is due to sig-
nificantly increased stromal infiltration in patients with-
out T-cell response (10.6/HPF vs. 5.9/HPF, p = 0.03).
Table 1: Panel of antibodies used in this study
Antibody Clone Antigen 
retrieval
Dilution Main cell reactivity Source
CD68 PGM1 Citrate 1:50 Macrophages Dako, Glostrup, Denmark
CD163 10D6 Citrate 1:100 Macrophages Novocastra, Newcastle upon Tyne, UK
S100 rabbit polyclonal Citrate 1:500 DC Dako
CD11c 5D1 Citrate 1:50 interdigitating DC, stromal DC Novocastra
DC-LAMP/CD208 104.G4 Protease 1:50 mature DC Immunotech, Marseille Cedex, France
DC-SIGN/CD209 DCN46 Citrate 1:100 stromal DC BD Pharmingen, San Diego, CA, USA
CD123 9F5 Citrate 1:10 plasmacytoid DC BD Pharmingen
CD1a 010 Citrate 1:50 Langerhans cells, interdigitating DC Dako
Langerin/CD207 12D6 Citrate 1:100 Langerhans cells NovocastraJournal of Translational Medicine 2007, 5:62 http://www.translational-medicine.com/content/5/1/62
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Immunohistochemical staining of macrophage and dendritic cell infiltration in colorectal cancer Figure 1
Immunohistochemical staining of macrophage and dendritic cell infiltration in colorectal cancer. (A) CD68 and (B) CD163 
expression of the macrophages (inset: double labeling CD163 (red)/S100 (brown) distinguishes CD163+ macrophages from 
S100+ DC). Dendritic cell populations with expression of (C) S100, (D) CD11c, (E) CD208, (F) CD209, (G) CD123 and (H) 
CD1a (inset: Langerin/CD207). (magnification ×200, inset ×400).Journal of Translational Medicine 2007, 5:62 http://www.translational-medicine.com/content/5/1/62
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There was also a trend towards increased CD11c infiltra-
tion in patients with systemic T-cell response (3.0 vs. 1.4,
p = 0.05). Cell infiltration determined by the other mark-
ers was not different between patients with and without
systemic T-cell response.
Macrophage/DC infiltration and stage of colorectal cancer
There is no single staining which is significantly increased
or decreased with regard to the stage in our study popula-
tion (total cell numbers). In a subset analysis, there was an
increase of stromal S100+ DC and CD163-positive macro-
phages in limited disease (S100: 11.1/HPF vs. 7.3/HPF, p
= 0.046; CD163: 11.0/HPF vs. 8.1/HPF, p = 0.06). Addi-
tionally, there was a trend toward increased CD11c infil-
tration in advanced disease (0.13/HPF vs. 0.98/HPF, p =
0.08).
Macrophage/DC infiltration and T cell/Treg infiltration
The correlation coefficients between various cell subsets
are listed in Table 3. Data on T cell infiltration have been
published previously [23]. After Bonferroni correction, we
found that the following pairs significantly correlated
with each other: CD123 – CD68, S100 – FOXP3, CD1a –
CD68, CD208 – FOXP3, and not surprisingly CD3 – CD8
and FOXP3 – CD3. Due to the fact that CD123, CD1a,
and CD208 are found only at very low infiltration levels,
we regard the positive correlation between S100-positive
DC and FOXP3-positive Treg (Pearson's correlation coef-
ficient 0.59, p < 0.001) the most important.
Macrophage and DC infiltration and survival
We found significantly better survival in patients with
high infiltration by S100-positive DC (p = 0.03, Figure
2A). To exclude a dominant role of S100+ macrophages,
not only did we calculate survival in relation to S100+ but
also CD163-negative cell infiltration (calculated from
double staining). This calculation confirmed a better sur-
vival for patients with high DC infiltration (p = 0.047).
This better survival was also found for S100+ DC infiltra-
tion of tumor stroma but not epithelial tissue. After stage
correction there was still a strong trend towards better sur-
vival of patients with higher S100-positive DC infiltration
(p = 0.06). Moreover, we found a trend towards better sur-
vival for increased infiltration with CD163-positive mac-
rophages (p = 0.07, Figure 2B). This trend was also
confirmed after stage correction (p = 0.07). Patients with
high stromal CD163+ macrophage infiltration survived
significantly longer (p = 0.01, Figure 2C).
Macrophage/DC infiltration and age and gender
We found a difference between male and female patients
for CD163+ cells. Female patients had 14.5/HPF and male
patients 10.2/HPF (p = 0.03) macrophages. None of the
other markers showed any differences between males and
females. A weak trend towards a negative correlation was
seen between age and stromal S100 DC infiltration (Pear-
son's = -0.332, p = 0.05). No relation to age was found for
the other infiltrating cell populations. It should be noted
that age had no impact on survival in our study popula-
Table 2: Infiltration of cells expressing DC or macrophage markers
CD68 CD163 S100 CD11c CD208 CD209 CD123 CD1a Langerin
Mean cell number per HPF ± SD 15.9 ± 8.8 12.4 ± 6.3 11.5 ± 7.3 1.8 ± 2.4 1.0 ± 1.5 2.8 ± 3.2 0.6 ± 1.0 2.2 ± 2.8 0.1 ± 0.3
Range 4.0 – 52.0 3.9 – 30.0 1.7 – 46.0 0- 11.7 0 – 7.0 0.1 – 16.1 0 – 5.5 0.2 – 12.4 0 – 1.1
At least 0.2 cells per HPF in % of samples 100% 100% 100% 95% 77.5% 97.5% 70% 100% 32.5%
Stromal infiltration cells/HPF 12.8* 9.7* 9.3* 1.3 0.6 2.2* 0.3 1.1 0.1
Epithelial infiltration cells/HPF 3.1 2.8 2.2 0.5 0.3 0.6 0.4 1.1 0.1
(Differences due to rounding error, * significantly increased compared to epithelial infiltration)
Table 3: Pearson's correlation coefficients between TAM/TADC and other tumor infiltrating immune cells
CD68 S100 CD11c CD163 CD208 CD209 CD1a FOXP3 CD3 CD8
CD123 0.541*** n.s. n.s. n.s. n.s. n.s. 0.331* n.s. n.s. 0.317*
CD68 1 0.361* n.s. n.s. n.s. n.s. 0.548*** n.s. n.s. n.s.
S100 1 n.s. n.s. 0.449** n.s. n.s. 0.592*** n.s. n.s.
CD11c 1 n.s. 0.475** n.s. n.s. n.s. n.s. n.s.
CD163 1 n.s. 0.343* 0.379* n.s. 0.457** 0.399*
CD208 1 n.s. n.s. 0.612*** 0.372* n.s.
CD209 1 0.342* n.s. n.s. n.s.
CD1a 1 n.s. n.s. n.s.
FOXP3 1 0.657*** 0.449**
CD3 1 0.930***
n.s. not significant, *p < 0.05, ** p < 0.01, ***p < 0.001Journal of Translational Medicine 2007, 5:62 http://www.translational-medicine.com/content/5/1/62
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tion. Survival did not different between patients above
and below the median (p = 0.54, log rank).
Discussion
Understanding the delicate interaction between innate
and adaptive immune response at the interface between
immune attack and immune suppression might help to
improve immunotherapeutic approaches in CRC. In the
present paper, we analyzed a potential relationship
between tumor-infiltrating macrophages and dendritic
cells with other immune cells and clinical parameters in
CRC. We applied a broad spectrum of markers to embrace
the manifoldness of different macrophage and dendritic
cell subsets.
S100 is not an absolutely exclusive but reliable DC marker
in CRC specimen [13,15]. Furthermore, we were able to
distinguish S100-positive dendritic cells from CD163-
positive macrophages by double staining for S100/
CD163; this is important, since macrophages can also
show weak expression of S100. Infiltration of the tumor
and the stroma by macrophages and DC was found in all
our specimens. However, the infiltration by macrophages
or DC ranged from a very low rate of 1.7 cell/HPF up to
46/HPF. This observation reflects the broad interindivid-
ual differences, which have already been described else-
where [15].
One primary endpoint of the present study was to investi-
gate the relationship between tumor-infiltrating macro-
phages, DC and a TAA-directed systemic T-cell response.
Interestingly, we found significantly increased infiltration
by DC in patients without systemic T-cell response. More-
over, tumor DC infiltration strongly correlates with infil-
tration of regulatory T cells. It is assumed that local
immature DC capture antigens, migrate to lymphoid tis-
sue, process the antigen and, after maturation, present the
antigen to specific immune cells like T cells [27]. Further-
more, we can assume that the DC found in our study are
primarily immature DC, since prior studies in human
CRC have shown that 1) only an mean of 1% (epithe-
lium) and 7% (stroma) of S100+ DC were positive for the
maturation marker CD208 [28] and 2) only very few
CD83+CD86+ DC were found in CRC [29]. In agreement
with this, we also showed in our analyses that only a small
number (1/HPF) of dendritic cells are CD208-positive.
Based on this knowledge about the function and presence
of DC, we hypothesize that tumor stroma infiltrating
immature DC primarily induce regulatory T cells as it is –
with some limitations – understood as one of their key
functions [30]. It remains speculative whether these Tregs
may in turn reduce the induction of TAA-specific T-cell
responses as we have previously shown as a weak trend
[23]. However, this could serve as a reasonable explana-
tion for the negative association between tumor-infiltrat-
ing DC (S100) and systemic TAA-directed T-cell response.
Our data confirm prior studies suggesting better survival
for patients with increased DC infiltration [13-15]. We
found a better survival for both high stromal and epithe-
lial DC infiltration. A bias concerning an interaction
between age, which negatively correlated with stromal DC
Kaplan Meier survival analyses of patients with high (solid) and low (dashed) cell infiltration in the tumor Figure 2
Kaplan Meier survival analyses of patients with high (solid) and low (dashed) cell infiltration in the tumor. A) Patients with high 
S100 infiltration have a significantly better survival (p = 0.03). B) Patients with high total CD163 tend to have a better survival 
(p = 0.07). C) Patients with high stromal CD163 infiltration have a significantly better survival (p = 0.01).
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infiltration, and survival in our study population was
excluded by Kaplan-Meier analysis, which showed that
survival did not differ in patients older and younger than
the median. Additionally, a bias with regard to the higher
S100 infiltration in lower stages was excluded by stage-
corrected survival analyses, which confirmed that high DC
(S100) infiltration correlates with better survival. This
effect is based on data of stromal infiltration by DC.
CD11c is a marker which is expressed on myeloid DC,
monocytes, and macrophages. Here, CD11c infiltration
was almost 10 times lower than S100 infiltration. CD11c
infiltration was increased in advanced disease and
increased in patients with systemic T-cell response. Thus,
CD11c-positive cells reacted differently than S100-posi-
tive cells.
During our analyses, we realized that dendritic cells
expressing CD123, CD208, CD209, CD1a and Langerin
do not seem to play a major role in the local immunology
of human colorectal cancer, since the infiltration fre-
quency of these CD123-positive plasmacytoid DC, DC
positive for CD208 and CD209, and CD1a/Langerin-pos-
itive Langerhans cells is very low.
We used two different markers to identify tumor-infiltrat-
ing macrophages: CD68 as a less specific lysosomal
marker and CD163 as a marker more specific for macro-
phages. CD68 + cells were the most frequent immune cell
determined in the present study (about 16/HPF). Interest-
ingly, no significant association was found between
CD68+ macrophages and systemic T-cell response, Treg
infiltration, and survival. Despite conflicting data in pre-
vious studies, earlier publications found better – but not
significantly better – survival in CRC patients with higher
macrophage infiltration [5,19].
CD163 is a macrophage/histiocyte associated scavenger
receptor, which has not been analyzed in colorectal cancer
thus far. An increase of CD163-positive cells in colonic
mucosa seems to play a role in mediating autoimmune
diseases, such as Crohn's disease [31]. Here, we found an
increase of CD163-positive macrophages in limited dis-
ease and a trend for better survival in patients with high
CD163 infiltration – also after correction for the stage of
disease.
While CD68+ macrophages were neither increased nor
decreased in limited or advanced stages, both S100 DC
and CD163 macrophages were increased in the tumor
stroma in limited disease (UICC I +II) compared to
advanced disease (UICC III + IV).
The present study adds new data to the ongoing discus-
sion on the interaction between innate and adoptive
immune system. Our data strongly support the hypothesis
that tumor-infiltrating DC are a key factor at the interface
between innate and adaptive immune response in malig-
nant disease. Tumor-infiltrating DC negatively interact
with the systemic antigen-specific T-cell response but
demonstrate a positive correlation with regulatory T cells
and a positive association with survival in CRC. These
data put tumor-infiltrating DC at the center of the relevant
immune response in CRC.
Abbreviations
CRC – colorectal cancer, Treg – regulatory T cell, MP –
mononuclear phagocytes, DC dendritic cells, TAM –
tumor-associated macrophages, TADC – tumor-associated
dendritic cells.
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